Stock Scorecard
Stock Summary for Sarepta Therapeutics Inc (SRPT) - $127.39 as of 4/26/2024 3:48:23 PM EST
Total Score
7 out of 29
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for SRPT
Positive earnings growth | |
P/E ratio less than Industry P/E Ratio | |
P/E ratio less than Sector P/E Ratio | |
P/E ratio that is half the growth rate (or less) | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Positive net income past year and 12 trailing months | |
Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for SRPT
Revenue growing by at least 20% average per year over the last 5 years | |
Market Capitalization under 2 billion | |
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for SRPT
Declared an ex-dividend date | |
Forward annual dividend rate greater than 2 | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Current ratio most recent quarter greater than 2 |
Bonus Criteria for SRPT
P/E ratio less than five-year Average P/E ratio | |
Last Price to 52 Week Low Ratio Less Than 1 | |
Total Cash Per Share > Last Day Price | |
P/S Ratio < 1 | |
P/B Ratio < 1 |
Latest News for for SRPT
Financial Details for SRPT
Company Overview |
|
---|---|
Ticker | SRPT |
Company Name | Sarepta Therapeutics Inc |
Country | USA |
Description | Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapies, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. The company is headquartered in Cambridge, Massachusetts. |
Sector Name | LIFE SCIENCES |
Industry Name | PHARMACEUTICAL PREPARATIONS |
Most Recent Quarter | 12/31/2023 |
Next Earnings Date | 6/6/2024 |
Stock Price History |
|
Last Day Price | 127.39 |
Last Day Price Updated | 4/26/2024 3:48:23 PM EST |
Last Day Volume | 0 |
Average Daily Volume | 689,662 |
52-Week High | 159.89 |
52-Week Low | 55.25 |
Last Price to 52 Week Low | 130.57% |
Valuation Measures |
|
Trailing PE | N/A |
Industry PE | 79.17 |
Sector PE | 56.64 |
5-Year Average PE | -14.63 |
Free Cash Flow Ratio | 7.07 |
Industry Free Cash Flow Ratio | 12.71 |
Sector Free Cash Flow Ratio | 30.65 |
Current Ratio Most Recent Quarter | 3.95 |
Total Cash Per Share | 18.03 |
Book Value Per Share Most Recent Quarter | 9.17 |
Price to Book Ratio | 13.43 |
Industry Price to Book Ratio | 5.66 |
Sector Price to Book Ratio | 22.15 |
Price to Sales Ratio Twelve Trailing Months | 9.28 |
Industry Price to Sales Ratio Twelve Trailing Months | 5.48 |
Sector Price to Sales Ratio Twelve Trailing Months | 5.17 |
Share Statistics |
|
Total Shares Outstanding | 93,855,000 |
Market Capitalization | 11,956,188,450 |
Institutional Ownership | N/A |
Dividends |
|
Ex-Dividend Date | N/A |
Last Dividend Amount | 0.00 |
Current Dividend Amount | 0.00 |
Dividend Aristocrat? | False |
Trailing Annual Dividend Rate | 0.00 |
Trailing Annual Dividend Yield | 1.26% |
Forward Annual Dividend Rate | 0.00 |
Forward Annual Dividend Yield | 0.00% |
5-Year Dividend Payments Count | 0 |
3-Year Average Dividend Yield | 0.00% |
5-Year Average Dividend Yield | 0.00% |
1-Year Dividend Growth Rate Percentage | 0.00% |
3-Year Dividend Growth Rate Percentage | 0.00% |
5-Year Dividend Growth Rate Percentage | 0.00% |
All-Time Dividend Growth Rate Percentage | 0.00% |
Dividend Payout Ratio | N/A |
Income Statement |
|
Quarterly Earnings Growth YOY | 0.00% |
Annual Earnings Growth | 23.81% |
Reported EPS 12 Trailing Months | -5.80 |
Reported EPS Past Year | 0.00 |
Reported EPS Prior Year | -6.12 |
Net Income Twelve Trailing Months | -535,977,000 |
Net Income Past Year | -535,977,000 |
Net Income Prior Year | -703,488,000 |
Quarterly Revenue Growth YOY | 53.50% |
5-Year Revenue Growth | 32.80% |
Balance Sheet |
|
Total Cash Most Recent Quarter | 1,691,800,000 |
Total Cash Past Year | 1,691,800,000 |
Total Cash Prior Year | 2,008,400,000 |
Net Cash Position Most Recent Quarter | 453,802,000 |
Net Cash Position Past Year | 453,802,000 |
Long Term Debt Past Year | 1,237,998,000 |
Long Term Debt Prior Year | 1,544,292,000 |
Total Debt Most Recent Quarter | 1,237,998,000 |
Equity to Debt Ratio Past Year | 0.41 |
Equity to Debt Ratio Most Recent Quarter | 0.41 |
Total Stockholder Equity Past Year | 859,337,000 |
Total Stockholder Equity Prior Year | 384,950,000 |
Total Stockholder Equity Most Recent Quarter | 859,337,000 |
Options |
|
Put/Call Ratio | 0.13 |
Has Options | Options Chain |
Liquidity Rating | |
Technical Analysis |
|
Yahoo Finance Chart | Yahoo Finance Chart |
MACD | -2.03 |
MACD Signal | -1.73 |
20-Day Bollinger Lower Band | 92.94 |
20-Day Bollinger Middle Band | 118.84 |
20-Day Bollinger Upper Band | 144.74 |
Beta | 0.95 |
RSI | 51.24 |
50-Day SMA | 114.52 |
200-Day SMA | 106.56 |
System |
|
Modified | 4/27/2024 12:04:36 PM EST |